| http://www.w3.org/ns/prov#value | - The aim of the study was to compare anticancer efficacy and adverse events, especially cardiovascular events.MATERIAL AND METHODS: In total, 910 eligible patients with T0-4, NX, M1, G1-3 prostate cancer with an Eastern Cooperative Oncology Group performance status of 0-2 were randomized to treatment with either PEP 240 mg i.m. twice a month for 2 months and thereafter monthly, or flutamide (Eulexi
|
